Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed, Auxilium Pharma, BioTelemetry, Progenics Pharma, and Ambit Biosciences

NEW YORK, December 9, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), BioTelemetry Inc (NASDAQ: BEAT), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Ambit Biosciences Corporation (NASDAQ: AMBI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

OncoMed Pharmaceuticals, Inc. Research Report    

On December 3, 2013, OncoMed Pharmaceuticals Inc. (OncoMed) announced a strategic collaboration with Celgene Corporation to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab. OncoMed stated that it will control and conduct initial clinical studies at which point Celgene has an option to license worldwide rights to up to six novel anti-CSC therapeutic candidates. According to the Company, OncoMed retains global co-development and U.S. co-commercialization rights for five of the six anti-CSC product candidates with 50/50 U.S. profit sharing, and royalties to be received in other territories.  Paul J. Hastings, OncoMed's Chairman and CEO said, "Through this major alliance with Celgene, we gain substantial resources that will enable us to continue to discover and develop new therapeutics independently while positioning OncoMed for substantial potential downstream value and profits. Importantly, by retaining co-development and co-commercialization rights to up to five biologic product candidates in our pipeline, we expect to add commercial capabilities to our core research and development competencies as we continue to build a premier oncology biotherapeutics company." The Full Research Report on OncoMed Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/a95c_OMED

--

Auxilium Pharmaceuticals Inc. Research Report

On December 4, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that the United States District Court for the District of Delaware granted Upsher-Smith Laboratories, Inc.'s motion for summary judgment with respect to its attempts to bring a testosterone gel product to market via its 505(b)(2) NDA using Auxilium's Testim® product as its reference listed drug. "We are very disappointed with the Court's decision," said Adrian Adams, CEO and President of Auxilium. "We remain committed to protecting and enforcing our intellectual property rights, and we are currently considering all avenues, including an appeal." The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

--

BioTelemetry Inc. Research Report  

On December 4, 2013, Biotelemetry, Inc. (Biotelemetry) (formerly known as CardioNet, Inc.) announced that the Centers for Medicare and Medicaid Services has published a reduction to the reimbursement for remote cardiac monitoring services, effective from January 1, 2014. According to the Company, the aforesaid reduction will impact all providers of remote cardiac monitoring services and will result in a 13.7% decrease to the national reimbursement rate for the MCOT^[TM] service. Joseph H. Capper, President and CEO of BioTelemetry, commented, "We are disappointed that CMS has taken this approach and will work hard to guide them to a more accurate assessment of the direct costs associated with these services and to the proven cost savings they deliver. However, it is important to note that this will not change the Company's strategic direction." The Full Research Report on BioTelemetry Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/d815_BEAT

--

Progenics Pharmaceuticals Inc. Research Report

On November 25, 2013, Progenics Pharmaceuticals Inc. (Progenics) announced that it is re-launching a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, Azedra™, in patients suffering from pheochromocytomas. Hagop Youssoufian, M.Sc., M.D., Executive Vice President of Research and Development for Progenics, said, "Azedra has the potential to be the first approved treatment for pheochromocytomas. Our team is energized by this opportunity to potentially bring a treatment option with improved dosing, safety and efficacy to patients suffering with these devastating conditions." The Company informed that after a successful completion of the phase 2b study, Progenics intends to submit a New Drug Application (NDA) and request priority review to receive FDA action on the application within six months instead of the standard ten. The Full Research Report on Progenics Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/ce17_PGNX

--

Ambit Biosciences Corporation Research Report

On December 3, 2013, Ambit Biosciences Corp. (Ambit Biosciences) announced a regulatory update after receiving feedback from the US Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead drug candidate, for the treatment of relapsed/refractory acute myeloid leukemia (AML). The Company informed that based on feedback from the FDA, Ambit Biosciences continues to move forward with its baseline plan to conduct a randomized, controlled Phase 3 clinical trial in relapsed/refractory FLT3-ITD positive AML patients with an overall survival endpoint as the basis for the potential initial approval of quizartinib. The Company added that it is continuing to work with the FDA to refine the appropriate starting dose for the Phase 3 trial. "We remain committed to moving quizartinib through its late stage development as expeditiously as possible, given the limited treatment options for FLT3 ITD positive AML patients who have relapsed or who are refractory to prior treatments," said Michael A. Martino, President and CEO of Ambit. The Full Research Report on Ambit Biosciences Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/1ff4_AMBI

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner